Kaufman et al. (2004) (46) and Staab et al. (2005) (51) |
3-23 months |
Pimecrolimus (n=129) or vehicle (n=66) for 4 wks in double-blind RCT,
followed by open-label treatment with pimecrolimus for 12 wks, then 4-wk
follow-up without treatment |
Mild to very severe |
Kapp et al. (2002) (47), Papp et al. (2004) (49), Papp et al. (2005)
(67) and McKenna et al. (2006) (52) |
3-23 months |
Pimecrolimus (n=204)
or vehicle (n=47) for 1 yr in double-blind RCT, followed by 1-yr
open-label phase consisting of 76 patients who received pimecrolimus for
2 years |
Mild to very severe |
Ho et al. (2003) (50) |
3-23 months |
Pimecrolimus (n=123) or vehicle
(n=63) for 6 wks in double-blind RCT, followed by 20-wk open-label
extension with pimecrolimus |
Mild to moderate |
Sigurgeirsson et al. (2015) (58) |
≥3-<12 months |
Pimecrolimus (n=1,205) or TCS (n=1,213) for 5 yrs in randomised,
open-label, parallel group study |
Mild to moderate |
Schneider et al. (2016) (30) and Spergel et al. (2015) (33) |
3-18
months |
Pimecrolimus (n=543) or vehicle (n=544) for 3 yrs in
double-blind RCT, followed by open-label extension, including only
patients without diagnosis of asthma, who were treated with pimecrolimus
for 3 yrs or until the age of 6 yrs |
Mild to very severe |